- Home
- Solutions
- By Diseases
- Autoimmune Ophthalmic Diseases
- Miller-Fisher Syndrome (MFS)
Miller-Fisher Syndrome (MFS) is considered rare and does not have standardized diagnostic and therapeutic strategies. Through high-quality preclinical research and development services, Protheragen works to enhance the understanding and therapeutic development of Miller-Fisher syndrome.
Miller-Fisher Syndrome (MFS) is a rare autoimmune form of Guillain-Barré Syndrome (GBS), defined by the classic triad of ophthalmoplegia (eye muscle paralysis), ataxia (loss of coordination), and areflexia (no reflexes). This condition often occurs after upper respiratory or gastrointestinal infections, with immunological self-mimicry causing damage to the peripheral nervous system. MFS is often connected to anti-GQ1b antibodies which were found in approximately 85% of the instances because such antibodies damage gangliosides located in the oculomotor nerves and in the dorsal root ganglia. Although most cases resolve spontaneously, some recurrent or severe cases decline respond to specific therapeutics approaches.
Fig.1 The underlying mechanism of MFS seems to be that of "molecular mimicry". (Noioso C. M., et al., 2022)
Cerebrospinal Fluid (CSF) Analysis
Analysis of cerebrospinal fluid (CSF) is crucial for the diagnosis of MFS. A common finding, albeit not an early one during the disease course, is hyperproteinorrachia, which denotes increased levels of protein in the CSF. - Anti-GQ1b antibody detection in the CSF has high specificity and reliable diagnostic value. This methodology enables differentiation and earlier diagnosis of MFS as compared to other similar neurological conditions.
Electrophysiological Studies
Nerve conduction studies (NCS) and electromyography (EMG) are crucial in evaluating the functional levels of the nervous system in MFS patients. The typical findings include diminished sensory nerve action potentials and absent H reflexes, indicative of sensory and motor pathway involvement. These studies assist in diagnosing the type of neuropathy, thus aiding in therapeutics plan formulation.
Novel Immunomodulatory Therapies
Targeted Therapies
Development of therapies that specifically address the underlying pathogenic mechanisms of MFS, such as:
Protheragen gives full attention to developing customized solutions for every client's need while paying careful attention to the processes involved in MFS therapeutics development. We partner with our clients to develop and implement achievable plans that meet the unique objectives of the given area of study.
Protheragen extends comprehensive preclinical research services which encompass the creation of diagnostic assays, verification of biomarkers, and assessment of therapeutic candidates. Each project is tailored to meet specific MFS research and development requirements through our bespoke services, enabling innovation and advancement within the discipline. If you are interested in our services, please feel free to contact us.
Reference
Copyright © Protheragen. All rights reserved.